Getting through the pandemic safely: employee protection remains top priority HARTMANN employs more than 10,500 people. The health of all employees, in addition to ensuring the security of supply as an essential supplier to healthcare systems, has been a particularly high priority since the beginning of the coronavirus pandemic. In view of the high numbers of infections, the Company decided to extend its coronavirus regulations for a transitional period after the government stopped requiring workers to provide certificates of vaccination, recovery or a daily negative test result in March of the current year. The measures include masking, social distancing, and hygiene rules, along with reduced office occupancy. Expanded vaccine program As early as December 2021, HARTMANN expanded its existing in-house coronavirus vaccination program in Germany to include vaccinations with mRNA vaccines from Biontech and Moderna. Since March 2022, the Company has also been offering the new Novavax coronavirus vaccine to previously unvaccinated employees. Back to normal Right at the start of the coronavirus pandemic, HARTMANN set up a global task force. It is responsible for the ongoing analysis and management of numerous pandemic-related measures. The task force is now guiding the Company on its gradual return back to normal. The focus remains on the protection of all employees, constantly ensuring supply chain security and safeguarding production at all sites. Coronavirus vaccinations at HARTMANN – now possible with the new active ingredient from Novavax since March 2022. 10 Inform first quarter 2022 | Additional updates
RkJQdWJsaXNoZXIy NDU5MjM=